As part of the NCCN 20th Annual Conference: Advancing the Standard of Cancer Care, a distinguished and diverse group of experts on value-based decision-making in oncology discussed guidelines and pathways and how their use has impacted bedside evidence-based decision-making for both physicians and patients. Moderated by Clifford Goodman, PhD, the roundtable also reflected on the criteria used to assess shared decision-making and the relationship between outcomes and cost when determining value.
You are looking at 1 - 3 of 3 items for
- Author: Clifford Goodman x
- Refine by Access: All x
Peter B. Bach, Stephen B. Edge, Linda House, Jennifer Malin, James L. Mohler, and Clifford Goodman
Christian G. Downs, Liz Fowler, Michael Kolodziej, Lee H. Newcomer, Mohammed S. Ogaily, W. Thomas Purcell, John C. Winkelmann, and Clifford Goodman
The Affordable Care Act (ACA) is a transformational event for health care in the United States, with multiple impacts on health care, the economy, and society. Oncologists and other health care providers are already experiencing many changes—direct and indirect, anticipated and unanticipated. A distinguished and diverse panel assembled at the NCCN 19th Annual Conference to discuss the early phase of implementation of the ACA. The roundtable touched on early successes and stumbling blocks; the impact of the ACA on contemporary oncology practice and the new risk pool facing providers, payers, and patients; and some of the current and future challenges that lie ahead for all.
Roy Beveridge, John Fox, Susan A. Higgins, Martin Kohn, John J. Mahoney, Lee N. Newcomer, Andrew von Eschenbach, and Clifford Goodman
Complex challenges face all players in the oncology landscape, from health care policy leaders and third-party payers, to practicing physicians and nurses, to patients and their families. In these unsteady economic times, possible answers proposed by some may represent part of the problem to others. A distinguished panel assembled at the NCCN 18th Annual Conference: Advancing the Standard of Cancer Care to explore the changing oncology landscape. This article is the synopsis of that discussion, with panelists shedding light on such issues as the astronomic cost of medical care, the need for clinicians to think outside the formulary, and the therapeutic decision-making process in the new world of “big data.”